• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson to settle derivatives lawsuits

Johnson & Johnson to settle derivatives lawsuits

August 2, 2012 By MassDevice staff

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said it’s reached agreements to settle a trio of derivatives lawsuits filed by shareholders seeking to reform the healthcare conglomerate after a spate of damaging recalls across its product portfolio.

New Brunswick, N.J.-based Johnson & Johnson revealed the agreements, which must still be approved by the U.S. District Court for New Jersey, in a recent regulatory filing.

The settlement agreement, which does not include any admission of guilt, would be in return for J&J agreeing to a series of corporate reforms and to pony up as much as $10.5 million in legal fees and expenses. Court approval could come as soon as next month, according to the filing.

Johnson & Johnson, current and former management "allegedly engaged in, approved of, or failed to remedy or prevent defective medical devices, improper pharmaceutical rebates, improper off-label marketing of pharmaceutical and medical device products, violations of current good manufacturing practice regulations that resulted in product recalls" and "failed to disclose the aforementioned alleged misconduct," according to court documents and the regulatory filing.

The agreements also cover a lawsuit filed over J&J’s $78 million settlement of a bribery scandal in April 2011. That deal put Foreign Corrupt Practices Act violations and kickback charges to rest, but triggered one of the lawsuits covered in the proposed settlements. The company admitted no responsibility for accusations in the U.S. and the U.K. that its DePuy Inc. unit earned more than $24 million in profits over eight years by bribing Greek orthopedic surgeons to buy its implants. The U.S. settlement also covers bribery charges over its pharmaceutical products and an alleged kickbacks scheme to win contracts under the United Nations Oil-for-Food program in Iraq.

The latest settlement agreements do not cover a lawsuit filed in the same Garden State court over former CEO William Weldon’s compensation. Weldon, who presided over  the spate of recalls that have bedeviled the healthcare giant for the past few years and made Dealbook’s worst CEOs list, got a 30% pay bump for 2012 and was slated to walk away with a cool $143.5 million when he retired in April.

Johnson & Johnson said its board is evaluating the lawsuit’s allegations and that it aims to have dismissed derivatives suits filed in New Jersey Superior Court that make the same claims as the cases the proposed settlements would cover.

Filed Under: Legal News, MassDevice Earnings Roundup, News Well Tagged With: 2012, Johnson and Johnson, Q2

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy